Burzynski Research Institute (BZYR) Other Non Operating Income (2012 - 2017)
Burzynski Research Institute (BZYR) posted Other Non Operating Income of $1000.0 for Q2 2017, up 1392.54% sequentially from $67.0 in Q4 2014.
Burzynski Research Institute (BZYR) Other Non Operating Income (2012 - 2017) Analysis & Trends
Burzynski Research Institute has reported Other Non Operating Income for 4 years, with the latest figure at $1000.0 in Q2 2017.
- Quarterly Other Non Operating Income changed N/A year-over-year to $1000.0 in Q2 2017, while the trailing twelve-month figure through Feb 2018 was $1000.0 (changed N/A YoY) and the FY2021 annual result came in at $97773.0, up 19454.6% from the prior year.
- Other Non Operating Income rose to $1000.0 in Q2 2017 per BZYR's latest filing, from $67.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $1000.0 in Q2 2017 and troughed at $67.0 in Q4 2014.
- A 3-year average of $405.67 and a median of $150.0 in 2013 frame the typical range for Other Non Operating Income.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2017 | 1,000.00 |
| Nov 30, 2014 | 67.00 |
| Feb 28, 2013 | 150.00 |
| May 31, 2012 | 100.00 |